N-[2-[N-[3-[4-(N-tert-butoxycarbonylaminomethyl)phenyl]propyl]-N-methylamino]ethyl]-3,4-methylenidioxybenzenecarboxamide | 496946-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-[2-[N-[3-[4-(N-tert-butoxycarbonylaminomethyl)phenyl]propyl]-N-methylamino]ethyl]-3,4-methylenidioxybenzenecarboxamide
• 英文别名: tert-butyl N-[[4-[3-[2-(1,3-benzodioxole-5-carbonylamino)ethyl-methylamino]propyl]phenyl]methyl]carbamate
• CAS: 496946-56-6
• 化学式: C₂₆H₃₅N₃O₅
• 分子量: 469.581
• InChiKey: PMQFAUNTYFSTLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1445250A1

  公开（公告）日：2004-08-11

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.

  本发明旨在提供一种新型低分子量胺衍生物，该衍生物被很好地吸收，毒性低，并且具有极高选择性的优异人类β-色氨酸蛋白酶抑制活性，其药学上可接受的盐，以及含有该衍生物作为活性成分的药物。本发明的药物可作为一种预防/治疗剂，用于被认为是由β-色氨酸蛋白酶引起的危机和发展的疾病，例如呼吸道疾病、过敏性疾病、炎症性肠病、皮肤过度增生疾病、血管水肿和类风湿性关节炎。
• Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
  申请人：Kato Yutaka

  公开号：US20050043304A1

  公开（公告）日：2005-02-24

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.